Perspectives on current recommendations for genetic testing in HCM

Authors

  • Lorenzo Monserrat Cardiology Department, Health In Code, A Coruña, Spain

DOI:

https://doi.org/10.21542/gcsp.2018.23

Abstract

[first paragraph of article]

Hypertrophic cardiomyopathy (HCM) is defined as a primary cardiac muscle disease characterized by the presence of myocardial hypertrophy in the absence of apparent causes for the observed degree of hypertrophy. This definition includes both familial and sporadic (apparently non-familial) forms of the disease. HCM is usually considered as a genetically determined condition. Current genotyping technologies allow for the identification of the genetic causes of the disease in 50 to 70% of the patients who fulfill clinical diagnostic criteria. However, the etiology of 30 to 40% of the cases remains elusive. This review is focused on the current role of genetic testing in HCM, and the potential benefits of the identification of the genetic etiology of the disease.

Downloads

Published

2018-10-24

Issue

Section

Review articles